Trial Profile
A retrospective, cohort study assessing effectiveness of Ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitors as second-line treatments for Non-Alcoholic Fatty Liver Disease patients with Type 2 Diabetes Mellitus who do not respond to incretin-based therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Mar 2016
Price :
$35
*
At a glance
- Drugs Ipragliflozin (Primary)
- Indications Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 08 Mar 2016 New trial record
- 25 Feb 2016 Results published in the Clinical Drug Investigation